Efficacy and toxicity of PD-1 inhibitor combined with induction chemotherapy for locally advanced laryngeal and hypopharyngeal cancers.

IF 2.9 3区医学 Q2 ONCOLOGY

American journal of cancer research Pub Date : 2025-05-15 eCollection Date: 2025-01-01 DOI:10.62347/HVRH6856

Tingting Zhao, Wan Liu, Rong Yan, Yanjie Ma, Xudong Wang, Minghui Wei

{"title":"Efficacy and toxicity of PD-1 inhibitor combined with induction chemotherapy for locally advanced laryngeal and hypopharyngeal cancers.","authors":"Tingting Zhao, Wan Liu, Rong Yan, Yanjie Ma, Xudong Wang, Minghui Wei","doi":"10.62347/HVRH6856","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the efficacy, toxicity, and voice rehabilitation outcomes of PD-1 inhibitors combined with induction chemotherapy (PCIC) compared to induction chemotherapy (IC) alone.Methods: A retrospective analysis was conducted on 250 patients with stage III/IVA squamous cell carcinoma of the larynx/hypopharynx treated between June 2021 and December 2023. After 1:1 propensity score matching, 216 patients (108 per group) were analyzed. Both groups received platinum-based induction chemotherapy, with the PCIC group receiving an additional PD-1 inhibitor, toripalimab. Efficacy was evaluated based on response rates and survival outcomes, while toxicity profiles and voice rehabilitation were assessed.Results: The PCIC group had significantly higher complete remission rates (81.48% vs. 65.74%; P = 0.021) and improved 1-year overall survival (62.96% vs. 49.07%; P = 0.040). The incidence of neutropenia and nausea was higher in the PCIC group (P < 0.05). Voice quality assessments showed worse objective vocal grade but better patient-perceived vocal quality in the PCIC group (both P < 0.05).Conclusion: The combination of PD-1 inhibitors with induction chemotherapy improve remission rates and survival in patients with locally advanced laryngeal and hypopharyngeal cancers. However, increased toxicity and voice rehabilitation challenges highlight the need for comprehensive patient support during treatment.","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 5","pages":"2193-2207"},"PeriodicalIF":2.9000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12163456/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/HVRH6856","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the efficacy, toxicity, and voice rehabilitation outcomes of PD-1 inhibitors combined with induction chemotherapy (PCIC) compared to induction chemotherapy (IC) alone.

Methods: A retrospective analysis was conducted on 250 patients with stage III/IVA squamous cell carcinoma of the larynx/hypopharynx treated between June 2021 and December 2023. After 1:1 propensity score matching, 216 patients (108 per group) were analyzed. Both groups received platinum-based induction chemotherapy, with the PCIC group receiving an additional PD-1 inhibitor, toripalimab. Efficacy was evaluated based on response rates and survival outcomes, while toxicity profiles and voice rehabilitation were assessed.

Results: The PCIC group had significantly higher complete remission rates (81.48% vs. 65.74%; P = 0.021) and improved 1-year overall survival (62.96% vs. 49.07%; P = 0.040). The incidence of neutropenia and nausea was higher in the PCIC group (P < 0.05). Voice quality assessments showed worse objective vocal grade but better patient-perceived vocal quality in the PCIC group (both P < 0.05).

Conclusion: The combination of PD-1 inhibitors with induction chemotherapy improve remission rates and survival in patients with locally advanced laryngeal and hypopharyngeal cancers. However, increased toxicity and voice rehabilitation challenges highlight the need for comprehensive patient support during treatment.

查看原文本刊更多论文

PD-1抑制剂联合诱导化疗治疗局部晚期喉癌和下咽癌的疗效和毒性。

目的：评价PD-1抑制剂联合诱导化疗（PCIC）与单独诱导化疗（IC）的疗效、毒性和语音康复效果。方法：回顾性分析2021年6月至2023年12月期间接受治疗的250例III/IVA期喉部/下咽鳞状细胞癌患者。经1:1倾向评分匹配，216例患者（每组108例）进行分析。两组均接受以铂为基础的诱导化疗，PCIC组接受额外的PD-1抑制剂托帕利单抗。根据反应率和生存结果评估疗效，同时评估毒性概况和语音康复。结果：PCIC组患者完全缓解率明显高于PCIC组(81.48% vs. 65.74%；P = 0.021)，提高了1年总生存率(62.96% vs 49.07%；P = 0.040)。PCIC组中性粒细胞减少和恶心发生率较高（P < 0.05）。语音质量评价显示PCIC组客观语音等级较差，患者感知语音质量较好（P < 0.05）。结论：PD-1抑制剂联合诱导化疗可提高局部晚期喉癌和下咽癌患者的缓解率和生存率。然而，增加的毒性和语音康复挑战突出了在治疗期间需要全面的患者支持。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American journal of cancer research ONCOLOGY-

自引率

3.80%

发文量

263

期刊介绍： The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.